# Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

> **NCT03370198** · PHASE1 · TERMINATED · sponsor: **Celyad Oncology SA** · enrollment: 1 (actual)

## Conditions studied

- Colon Cancer Liver Metastasis

## Interventions

- **BIOLOGICAL:** NKR-2 cells

## Key facts

- **NCT ID:** NCT03370198
- **Lead sponsor:** Celyad Oncology SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-01-15
- **Final completion:** 2018-12-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Difficulties in patient recruitment and clinical strategy modification based on new clinical data generated in the NKR-2 early development.
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370198, "Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03370198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*